AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor being developed for the management of fibromyalgia. Esreboxetine is the SS-enantiomer of racemic reboxetine.

This article originally appeared in the National Association of EMS Physicians blog and is reprinted here with permission. By ...

Spikes in blood sugar after eating may be more dangerous for the brain than previously thought. In a massive genetic study, ...

Genetic and clinical data suggest dietary factors may influence autism risk via immune pathways, highlighting the need for ...

Microsoft alone runs approximately 100,000 A/B tests each year to continuously optimize products. A famous Gmail experiment, ...

Microsoft today issued patches to plug at least 113 security holes in its various Windows operating systems and supported ...

Although it'd be incorrect to say Voyagers was the very first to this starting line, it still counts as an early adopter, ...

Microsoft’s January 2026 Patch Tuesday fixes 114 Windows flaws, including an actively exploited Desktop Window Manager bug ...

A study led by researchers from the University of Liverpool has found that spikes in blood sugar after meals may increase the ...

This lesson-filled episode makes the case for capital "H" History as an investor's secret weapon -- and for why perspective, ...

Helping women to keep their blood pressure at normal levels could reduce their risk of experiencing pregnancy complications, ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...